Carapezzi William R JR 4

4 · PFIZER INC · Filed Mar 1, 2021

Form 4

Period: 2021-02-25

Executive Vice President

Transactions

Exercise/Conversion
Common Stock
2021-02-25$22.89/sh+27,222$623,112→ 71,553 total
Tax Payment
Common Stock
2021-02-25$33.82/sh−2,983$100,885→ 68,570 total
Exercise/Conversion
Stock Appreciation Rights
2021-02-25−27,222→ 0 total
Exercise: $22.89From: 2021-02-25Exp: 2021-02-25→ Common Stock (27,222 underlying)
Award
Stock Appreciation Rights
2021-02-25+37,925→ 37,925 total
Exercise: $33.82From: 2026-02-25Exp: 2026-02-25→ Common Stock (37,925 underlying)
Award
Stock Appreciation Rights
2021-02-25+32,769→ 32,769 total
Exercise: $33.82From: 2028-02-25Exp: 2028-02-25→ Common Stock (32,769 underlying)
Tax Payment
Common Stock
2021-02-25$34.76/sh−17,618$612,402→ 50,952 total

Holdings

Footnotes (6)

[F1]The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
[F2]The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
[F3]The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
[F4]Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
[F5]The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
[F6]The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

Documents

1 file